KalVista Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>KP</div>
KALV -- USA Stock  

USD 16.05  0.12  0.75%

KalVista Pharmaceuticals Receivables is fairly stable at the moment as compared to the past year. KalVista Pharmaceuticals reported Receivables of 16.53 Million in 2019. Total Debt is likely to climb to about 4 M in 2020, whereas Revenue Per Employee is likely to drop slightly above 122 K in 2020. In spite of fairly stable forward indicators, KalVista Pharmaceuticals is not utilizing all of its potentials. The recent stock price fuss, may contribute to a near-short-term swings for the sophisticated investors. KalVista Pharmaceuticals current probability of distress is under 5 percent. Will sophisticated investors continue to be optimistic, or should we expect a sell-off?
Published over three months ago
View all stories for KalVista Pharmaceuticals | View All Stories
Does KalVista Pharmaceuticals (NASDAQ:KALV) have stable forward indicators based on the latest climb?
On a scale of 0 to 100, KalVista Pharmaceuticals holds a performance score of 7. The company secures a Beta (Market Risk) of 0.6565, which conveys possible diversification benefits within a given portfolio. Let's try to break down what KalVista's beta means in this case. As returns on the market increase, KalVista Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding KalVista Pharmaceuticals will be expected to be smaller as well. Although it is vital to follow KalVista Pharmaceuticals price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for KalVista Pharmaceuticals, which you can use to evaluate the performance of the firm. Please exercises KalVista Pharmaceuticals semi variance, and the relationship between the treynor ratio and daily balance of power to make a quick decision on whether KalVista Pharmaceuticals current price movements will revert.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include KalVista Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential KalVista Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although KalVista Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in KalVista Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on KalVista Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of KalVista Pharmaceuticals fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of KalVista Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of KalVista Pharmaceuticals shares is the value that is considered the true value of the share. If the intrinsic value KalVista is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares KalVista Pharmaceuticals. Please read more on our fundamental analysis page.

Are KalVista Pharmaceuticals Earnings Expected to grow?

The future earnings power of KalVista Pharmaceuticals involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of KalVista Pharmaceuticals factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. KalVista Pharmaceuticals stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of KalVista expected earnings.

How KalVista utilizes its cash?

To perform a cash flow analysis of KalVista Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash KalVista Pharmaceuticals is receiving and how much cash it distributes out in a given period. The KalVista Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. KalVista Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. KalVista Pharmaceuticals reported Net Cash Flow from Operations of (11.25 Million) in 2020

KalVista Pharmaceuticals Gross Profit

KalVista Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing KalVista Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show KalVista Pharmaceuticals Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Breaking down the case for KalVista Pharmaceuticals

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of KalVista Pharmaceuticals is not uncomon. There are few distinct groups of KalVista Pharmaceuticals stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of KalVista is distributed among investors.

Ownership Allocation

KalVista Pharmaceuticals holds a total of 17.9 Million outstanding shares. The majority of KalVista Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in KalVista Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in KalVista Pharmaceuticals. Please pay attention to any change in the institutional holdings of KalVista Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Also note that almost seven hundred sixteen thousand invesors are currently shorting KalVista Pharmaceuticals expressing very little confidence in its future performance.

Retail Investors-4.04

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. KalVista Pharmaceuticals has an asset utilization ratio of 22.35 percent. This indicates that the company is making $0.22 for each dollar of assets. An increasing asset utilization means that KalVista Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
49.1 M
Tax Assets
13.2 M
Current Assets49.1 Million75.08
Assets Non Current3.1 Million4.74
Tax Assets13.19 Million20.17

How will KalVista sophisticated investors react to the next fall?

Latest Sortino Ratio is up to 0.07. Price may fall again. KalVista Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate KalVista Pharmaceuticals individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about KalVista Pharmaceuticals future systematic risk.

Our Final Perspective on KalVista Pharmaceuticals

While some other entities in the biotechnology industry are either recovering or due for a correction, KalVista Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of KalVista as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to KalVista Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of KalVista Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com